|Articles|June 27, 2011
Linagliptin cardiovascular safety profile appears superior to glimepiride
Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.
Advertisement
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.
Advertisement
Latest CME
Advertisement
Advertisement














